Dr. Shuai is a Senior Associate focusing on healthcare investment at WI Harper Group based in the Beijing office. He has deep understanding in the healthcare field with 2 years of experience in venture capital and 8 years of experience in biomedical & pharmaceutical academic research.
Prior to joining WI Harper Group, Dr. Shuai served as the healthcare Investment Director in Beijing BW Invest (BWI) where he worked mainly in healthcare fund raising (~4 billion RMB), investment strategy formulation and investment opportunity sourcing.
Before entering the VC industry, he was trained as a postdoctoral fellow and worked on many gene therapy innovations under the supervision of Prof. Demin Zhou, the Dean of School of Pharmaceutical Science and the Director of SKLNBD in Peking University Health Science Center (HSC). Dr. Shuai’s main scientific research focus during his Ph.D. was on the mechanism of cancer progression and translational medicine. He has published several papers in top peer-reviewed journals during his academic career. In addition, Dr. Shuai was the head of the Postdoctoral Association of PKU HSC as well as one of the appointed ministers of the Postdoctoral Association of PKU.
Dr. Shuai holds a Ph.D. degree and postdoctoral experience in Peking University Health Science Center.